SKYRIZI 75 MG / 0.83 ML
RISANKIZUMAB : 75 MG / 0.83 ML · DIN 02487454 · ABBVIE CORPORATION
Health Canada status: CANCELLED POST MARKET
What is SKYRIZI?
SKYRIZI 75 MG / 0.83 ML contains RISANKIZUMAB : 75 MG / 0.83 ML. It is listed in the Health Canada Drug Product Database under DIN 02487454, held by ABBVIE CORPORATION, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 28-Jan-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02487454 |
|---|---|
| Brand name | SKYRIZI |
| Generic / active ingredient | RISANKIZUMAB : 75 MG / 0.83 ML |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 75 MG / 0.83 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L04AC18 RIZANKIZUMAB |
| AHFS class | 84:06.28 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 28-Jan-2025 |
| Original market date | 2019-05-13 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code L04AC18 RIZANKIZUMAB. 5 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SKYRIZI | 150 MG / 1 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02519283 |
| SKYRIZI | 150 MG / 1 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02519291 |
| SKYRIZI | 180 MG / 1.2 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02552507 |
| SKYRIZI | 360 MG / 2.4 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02532093 |
| SKYRIZI | 60 MG | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02532107 |
| SKYRIZI | 90 MG / 1 ML | SOLUTION | ABBVIE CORPORATION | APPROVED | DIN 02546922 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.